A Eggermont

524 total citations
9 papers, 377 citations indexed

About

A Eggermont is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, A Eggermont has authored 9 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Genetics. Recurrent topics in A Eggermont's work include Cutaneous Melanoma Detection and Management (3 papers), Melanoma and MAPK Pathways (3 papers) and Virus-based gene therapy research (2 papers). A Eggermont is often cited by papers focused on Cutaneous Melanoma Detection and Management (3 papers), Melanoma and MAPK Pathways (3 papers) and Virus-based gene therapy research (2 papers). A Eggermont collaborates with scholars based in Netherlands, United States and Belgium. A Eggermont's co-authors include Ulrich Keilholz, Axel Hoos, Natalie Sacks, Kristen Hege, Giorgio Parmiani, Hans Loibner, Brent A. Blumenstein, Walter J. Urba, Mario Sznol and Geoffrey Nichol and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Chromatography A and International Journal of Cancer.

In The Last Decade

A Eggermont

8 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A Eggermont Netherlands	6	216	178	173	47	46	9	377
Rebecca Patenia United States	14	223 1.0×	312 1.8×	154 0.9×	16 0.3×	40 0.9×	24	541
Stephan Bernhardt Germany	10	208 1.0×	157 0.9×	277 1.6×	45 1.0×	120 2.6×	22	498
Huiyin Lee Singapore	8	91 0.4×	142 0.8×	213 1.2×	61 1.3×	104 2.3×	9	438
Hsin-Wei Liao United States	5	295 1.4×	177 1.0×	407 2.4×	53 1.1×	74 1.6×	5	664
Delphine Fontaine France	9	87 0.4×	65 0.4×	156 0.9×	44 0.9×	69 1.5×	12	319
Bruno Gomes Canada	10	171 0.8×	71 0.4×	176 1.0×	78 1.7×	52 1.1×	38	422
Françoise Silvy France	12	169 0.8×	169 0.9×	273 1.6×	22 0.5×	98 2.1×	25	501
Emily J. Lelliott Australia	9	195 0.9×	107 0.6×	181 1.0×	43 0.9×	25 0.5×	10	337
Seo Hee Nam South Korea	14	124 0.6×	78 0.4×	251 1.5×	24 0.5×	79 1.7×	24	446
Kota Itahashi Japan	8	173 0.8×	155 0.9×	109 0.6×	69 1.5×	41 0.9×	16	328

Countries citing papers authored by A Eggermont

Since Specialization

Citations

This map shows the geographic impact of A Eggermont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Eggermont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Eggermont more than expected).

Fields of papers citing papers by A Eggermont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A Eggermont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Eggermont. The network helps show where A Eggermont may publish in the future.

Co-authorship network of co-authors of A Eggermont

This figure shows the co-authorship network connecting the top 25 collaborators of A Eggermont. A scholar is included among the top collaborators of A Eggermont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A Eggermont. A Eggermont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Agarwala, Sanjiv S., Ulrich Keilholz, David Hogg, et al.. (2007). Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. Journal of Clinical Oncology. 25(18_suppl). 8510–8510. 54 indexed citations

Suciu, Stefan, et al.. (2006). Serum S100B protein evaluation in an EORTC randomized melanoma trial: A first report. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 29(1). 75–78.

Hoos, Axel, Giorgio Parmiani, Kristen Hege, et al.. (2006). A Clinical Development Paradigm for Cancer Vaccines and Related Biologics. Journal of Immunotherapy. 30(1). 1–15. 197 indexed citations

Guetens, G., Gert De Boeck, Martin Highley, et al.. (2002). Hyphenated techniques in anticancer drug monitoring. Journal of Chromatography A. 976(1-2). 239–247. 22 indexed citations

Guetens, G., Gert De Boeck, Michelle Wood, et al.. (2002). Hyphenated techniques in anticancer drug monitoring. Journal of Chromatography A. 976(1-2). 229–238. 16 indexed citations

Westphal, Johan R., Anneke Geurts‐Moespot, Fred C.G.J. Sweep, et al.. (2000). Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators. International Journal of Cancer. 86(6). 760–767. 46 indexed citations

Lejeune, Ferdy J., et al.. (1997). Treatment of in-transit melanoma metastases with tumour necrosis factor (TNF-??) and chemotherapy administered in isolated limb perfusion (ILP). Melanoma Research. 7(Supplement 1). S48–S48. 2 indexed citations

Lejeune, F., D. Liénard, A Eggermont, et al.. (1995). [Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience].. PubMed. 82(7). 561–7. 3 indexed citations

Lejeune, F., D Liénard, A Eggermont, et al.. (1994). Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma.. PubMed. 43(4). 191–7. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact